A carregar...

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma

A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to id...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Kidney Cancer VHL
Main Authors: Bayrak, Omer, Sen, Haluk, Bulut, Ersan, Cengiz, Beyhan, Karakok, Metin, Erturhan, Sakip, Seckiner, Ilker
Formato: Artigo
Idioma:Inglês
Publicado em: Codon Publications 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5345528/
https://ncbi.nlm.nih.gov/pubmed/28326248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2014.10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!